Articles tagged with Antidepressants
A third of patients with major depressive disorder (MDD) fully recovered from symptoms after initial treatment with antidepressant medication. Nearly 47% showed a response rate, with one in three achieving symptom-free state.
A study by Karolinska Institutet found that alcohol consumption significantly increases the risk of violent behavior, with a 13.2-fold higher risk within 24 hours. Use of certain medications, such as benzodiazepines and antidepressants, was associated with a decreased risk of violence.
Dr. Raz examines inconsistencies in antidepressant data for treating child and adolescent depression, highlighting the need for stronger evidence and questioning the safety of SSRIs for this age group.
Selective serotonin reuptake inhibitors (SSRIs) increase nerve impulse-carrying axon density in the frontal and parietal lobes, controlling emotions and motivation. This growth may explain why antidepressants take time to work, with effects seen within hours but clinically meaningful results taking weeks.
Researchers have discovered a new drug that raises the level of endocannabinoids, providing measurable antidepressant effects. The study found similar results to commonly prescribed antidepressants, suggesting URB597 as a safer, non-addictive alternative for pain and depression treatment.
Researchers found a twofold increase in adolescent depression visits between 1995 and 2002, with medication use rising from 47% to 52% and psychotherapy dropping from 83% to 68%. SSRIs accounted for 76% of prescribed antidepressants during this period.
A two-year, open-label trial demonstrated that adults with ADHD experienced significant long-term symptom control when treated with once-daily ADDERALL XR. The treatment showed a good tolerability profile and was significantly associated with improved quality of life.
A new approach to preventing SAD by starting antidepressant treatment in the fall has shown promise. Early intervention with bupropion-XL reduced the risk of fall-winter depression by 44% in patients with a history of recurring episodes.
A new report by Express Scripts, Inc. found that U.S. consumers could have saved $20 billion in 2004 by using more generic drugs, with the most dramatic savings potential existing for generic gastrointestinals and anti-cholesterol medications.
A survey of 44 medications found that 43 were cheaper in Canada than in the US, with potential savings of up to 24% per dose. Second-generation antidepressants showed similar efficacy and safety compared to other options, making choosing an antidepressant difficult for patients.
Researchers are exploring novel mechanisms for antidepressant drug action, hoping to develop better treatments for depression. The study aims to identify compounds that facilitate neurogenesis, increasing the potential for innovative therapies.
A new statistical analysis of paroxetine trials reveals a significantly higher rate of suicide attempts among adults compared to placebo groups. The study confirms that all SSRIs increase suicidal tendencies in depressed adults, with increased intensity over time.
Researchers found that riluzole, a glutamate modulating agent, reduced symptoms in 35% of patients with OCD. The study suggests that riluzole may represent a novel treatment intervention for certain anxiety and mood disorders.
The study highlights the need for personalized treatment approaches in postherpetic neuralgia. A quantitative systematic review of analgesic therapy found that treatments only worked in selected patients, suggesting a range of underlying mechanisms causing pain in different individuals.
A study of depressed heart patients found that those with low heart rate variability were nearly three times more likely to die after a heart attack. Researchers hope that treating depression and correcting heart rate variability may offer improved survival rates for these patients.
A new study suggests that antidepressants can help reduce the risk of heart attacks and death among patients who have had a heart attack and are experiencing depression. The ENRICHD study found that patients taking antidepressants had a 43% lower risk of death or recurrent non-fatal heart attack, compared to those not taking them.
A study found that antidepressants reduced the risk of death and non-fatal heart attacks by 43% in depressed heart attack patients. The analysis was based on data from the Enhancing Recovery in Coronary Heart Disease clinical trial, which randomized 2,481 patients with depression or social isolation between 1996 and 1999.
Researchers have found that bipolar disorder is associated with difficulties modulating brain regions that detect error and promote accurate responses. Additionally, a two-pronged pharmacologic approach of both a mood stabilizer and an antipsychotic may be necessary to treat both the depressive and manic phases of bipolar disorder.
The NIH State-of-the-Science panel recommends a broader use of cognitive and behavioral therapies to treat chronic insomnia, which has limited proven options. Research suggests that these methods can be effective in treating insomnia when combined with relaxation training.
Researchers found limited evidence to support the effectiveness of 10 commonly prescribed medications for insomnia, including trazodone, which is often used as a first-line treatment.
Newborns exposed to antidepressants in late pregnancy had a significantly increased risk of respiratory complications and special-care nursery admission. Strategies for managing maternal depression during pregnancy include gradual tapering and cessation of medication, but more research is needed.
Exposure and response prevention therapy is shown to be effective in reducing OCD symptoms in children, with benefits lasting after treatment ends. Medication therapy also reduces symptoms but does not provide a cure for the disorder.
Researchers found that both medication (nefazodone) and psychotherapy (CBASP) are effective in treating chronic depression even when the initial treatment fails. The study showed that switching between these two treatments resulted in improved symptoms for many patients, suggesting a strong basis for adjusting treatment plans.
Researchers found that actor-patients' requests for medications increased prescribing for depression. The study suggests that direct-to-consumer marketing can boost familiarity with potential treatments and improve initial care for patients.
A randomized trial found that patients' requests for medication, influenced by direct-to-consumer advertising, significantly impacted physicians' prescribing decisions. Patients making general requests had the highest prescribing rates, while those with no request received the lowest rate.
The study found that doctors prescribed antidepressants more often when patients asked for them, with 53% of the time when Paxil was requested. This raises concerns about the overuse of antidepressants in mild cases and the impact of direct-to-consumer advertising on healthcare quality.
A study in mice suggests that dopamine and serotonin neurotransmitters sometimes interact, causing delays in mood stabilization. This interaction may lead to alternative approaches for developing antidepressant treatments that target serotonin entry into dopamine terminals.
Researchers found that SSRIs increase serotonin levels in synapses, but also 'trick' dopamine transporters into retrieving serotonin, causing cosignaling. This complex effect may explain delayed antianxiety effects and behavioral abnormalities in children.
A randomized trial of 240 moderately to severely depressed patients found that cognitive therapy was as effective as antidepressant medication in achieving response and remission. The study supports the idea that cognitive therapy can be a viable treatment option for severe depression, even when provided by experienced therapists.
A recent study reveals that cognitive therapy is as effective as antidepressant medication in treating depression, but with a lasting impact even after treatment concludes. Cognitive therapy equips patients with skills to manage problems and emotions, outperforming medication in preventing relapses over time.
Researchers found changes in prefrontal brain function during a placebo lead-in predicted adverse effects in subjects who received an antidepressant. This study's unique design uses quantitative electroencephalography (QEEG) imaging technique cordance to identify individuals at risk of side effects.
A study published in Heart found that antidepressants may explain the increased risk of heart attack associated with their use. Patients who recently started antidepressants were twice as likely to have a heart attack within seven days compared to those who hadn't taken the medication before.
A study of surgically implanted electrodes in patients with refractory depression found significant clinical response in four out of six participants, with sustained improvement through six months. The technique involves high-frequency electrical stimulation to modulate brain activity in the subgenual cingulate region.
Researchers found no significant association between antidepressant use and suicide rates in the US. Instead, they suggest that untreated depression is a major contributor to suicidal behavior, particularly among men and young people.
A study published in the American Journal of Preventive Medicine found that exercising moderately intense aerobics for 30-35 minutes per day reduced depressive symptoms by an average of 47% after 12 weeks. The study included 80 adults with mild to moderate depression and showed similar results to antidepressant medications.
This article discusses the association between non-hazardous alcohol consumption and injury, as well as barriers to treating depression among young adults. Studies find that excessive drinking causes significant injuries, while negative attitudes towards treatment may prevent youth from accepting diagnosis and care.
Common antidepressants lower effects of tamoxifen in many women, with different SSRIs affecting active tamoxifen byproducts in the blood. Genetic testing may help identify groups that benefit more from one SSRI than another.
A study found that women taking SSRIs with CYP2D6 variant alleles had lower tamoxifen metabolite levels, potentially impacting treatment efficacy. The authors suggest testing CYP2D6 genetic variants to personalize tamoxifen therapy.
Researchers found a genetic variation in the CRH gene associated with a 70% greater reduction in anxiety and 30% greater reduction in depression in response to certain antidepressants. This discovery shows promise in helping physicians tailor prescriptions to specific people, offering a more targeted approach to treating depression.
A mutant gene that results in 80% less serotonin production has been identified in patients with unipolar major depression, with over 10% of cases carrying the mutation. The study suggests a potential molecular mechanism for aberrant serotonin function in neuropsychiatric disorders.
A recent study found that combining SAMe with antidepressant medication improved symptoms in 50% of participants and led to complete remission in 43% after six weeks. The study, led by Massachusetts General Hospital, investigated the efficacy of SAMe in patients with continuing symptoms despite initial treatment.
The use of celebrities to market drugs and diseases is a practice that raises concerns about public health and transparency. According to investigative reporter Ray Moynihan, this practice can lead to a lack of balance in the public debate about major health problems, as well as a failure to disclose potential conflicts of interest.
A study published in Archives of Internal Medicine found a significant association between antidepressant use and risk of abnormal bleeding. The risk increased with the degree of serotonin reuptake inhibition, particularly for drugs with high levels of inhibition, which were associated with a 2.6-fold increased risk of bleeding events.
Research suggests that nicotine receptors in the brain play a crucial role in antidepressant medication's effectiveness. The study found that blocking these receptors can accelerate emotional relief, particularly for patients who are suicidal or unresponsive to current treatments.
Researchers at Northwestern Memorial Hospital are testing a new Transcranial Magnetic Stimulation (TMS) treatment for major depression. The study aims to prove the effectiveness of TMS as a treatment alternative and compare its effects with placebo, with the goal of securing FDA clearance for clinical use.
A study found that combining antidepressant medication nortriptyline with a nicotine patch significantly increased smoking cessation rates at six months. The treatment showed a 23% success rate, compared to 10% for those receiving a placebo. However, participants taking nortriptyline experienced more side effects.
A UCSF study reveals that long-term medication and counseling can help smokers quit successfully, with 50% of participants abstinent after one year. The treatment program combined antidepressant nortriptyline with counseling for extended periods, showing better results compared to short-term options.
A 12-week study found that combining sertraline and CBT was more effective than treatment with just one or the other in reducing symptoms of obsessive compulsive disorder (OCD) in adolescents. CBT alone was also shown to be effective, particularly at the University of Pennsylvania site.
A randomized controlled trial found that patients treated with cognitive-behavioral therapy (CBT) alone or in combination with medication showed a substantially higher probability of improvement. The combined treatment proved more effective than CBT alone and sertraline alone in treating children and adolescents with OCD.
A recent study found that New York City residents' mental health visits rose less than expected after the 9/11 attacks. The majority of residents did not seek additional mental health services or medication use following the disaster, with only a few percent showing increased utilization.
A study found that one in six chronically ill adults skip medication due to cost, with those paying more out-of-pocket or having no coverage being the most likely. The researchers estimate that this skimping leads to over a million Americans using less medication and 1.6 million missing doses.
Parkinson's disease is often associated with depression, a condition that can significantly impact patients' lives. Research suggests that depression is part of the illness and not just a reaction to the disease.
The new guideline suggests tricyclic antidepressants, gabapentin, lidocaine skin patch, and opioids as effective in reducing pain from postherpetic neuralgia. However, the long-term effects of these treatments are not yet supported by sufficient data.
Experts dispute FDA warnings on antidepressants and suicidal risk, citing limited data for children and adolescents. Studies show a decrease in suicides over years of growing SSRI use, but caution is advised when interpreting the data.
A recent clinical trial demonstrated the effectiveness of duloxetine in reducing pain and improving disease symptoms in female fibromyalgia patients. The study showed significant improvements in tender point measures and pressure pain threshold, with benefits also observed in emotional and physical functioning.
A study by Dr. Kurt Kroenke found that depression is a risk factor for pain symptoms, with muscle pain and headaches being two or three times more common in people with depression. Physical symptoms may not respond to antidepressant treatment as well as emotional symptoms, and can linger longer.
A study by UT Southwestern Medical Center found that teens with depression experience significant improvement when treated with a combination of medication and cognitive-behavior therapy. The treatment resulted in a 71% improvement rate, compared to 60% for those taking Prozac alone or 43% for those receiving only therapy.
The TADS clinical trial found combined antidepressant and talk therapy treatment yielded the best results, followed by antidepressants alone. Talk therapy on its own was no more effective than placebo.
Stanford and Packard researchers found that nicotine patches were equally effective in adolescents regardless of antidepressant medication. Most teens reduced tobacco usage, with some achieving complete abstinence after 10 weeks. The study marks a promising breakthrough in treating teen smoking addiction.
The study suggests that the risk of suicidal behavior is similar among users of different antidepressant drugs, including SSRIs and tricyclic antidepressants. The risk of suicidal behavior is highest in the first month after starting treatment, particularly within the first nine days.